Questions and Answers to support the implementation of the ...
a transition period for the implementation of the new requirements and/ or where the GVP modules are not yet available. Volume 9A remains the reference as applicable until the transition period ends or
Download Questions and Answers to support the implementation of the ...
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Connect Care: Implementation Timeline
albertahealthservices.caWAVE 1 - NOVEMBER 3, 2019 1 2 3 EDMONTON ZONE Suburban acute and Combined acute and long term care sites PHARMACY, ALBERTA PUBLIC LABS & DI WAVE 3 - Sites in: Suburban Edmonton MAY 2020 4 WAVE 5 - APRIL 2021 CALGARY ZONE Foothills Medical Centre (including associated clinics
Redesigned Uniform Residential Loan Application (URLA ...
www.fanniemae.comRedesigned Form 1003 and DU Spec | June 2019 Implementation Timeline Feb. 1, 2019 Directly integrated lenders and TSPs may begin testing DU Spec
TRANSITION AND IMPLEMENTATION GUIDANCE - opm.gov
www.opm.govTransition Instructions – Current STEP Employees . Frequently Asked Questions for STEP Transition . Transition Instructions – Current SCEP Employees
Managing Change and Transition - University of Victoria
www.uvic.ca1. Look for ways to decrease unnecessary demands on existing resources.Leaders need to consider the aggregate effect of incremental changes. Change projects …